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ABSTRACT 
 
OBECTIVE: Biomarkers play a pivotal role in heart failure (HF) management. Reference 
values and insights from studies in adults cannot be extrapolated to the paediatric population 
due to important differences in pathophysiology and compensatory reserve. We assessed the 
diagnostic utility of four novel biomarkers in paediatric HF. 
METHODS: Mid-regional (MR) pro-Atrial Natriuretic Peptide (proANP), sST2, Growth 
Differentiation Factor-15 (GDF-15), MR-proAdrenomedullin (proADM) and N-terminal pro-
B Natriuretic Peptide (NT-proBNP) were measured in 114 patients and 89 controls. HF was 
defined as presence of HF symptoms and/or abnormal systolic ventricular function. Receiver-
operating characteristics were plotted and the area under the curve (AUC) measured. This was 
repeated for subgroups with cardiomyopathy and congenital heart disease (CHD). Ventricular 
systolic function was measured by magnetic resonance or echocardiography. Reference 
values were calculated according to current guidelines.  
RESULTS: The AUC for diagnosing HF was 0.76 for MR-proANP (CI: 0.70–0.84) and 0.82 
for NT-proBNP (CI: 0.75–0.88). These parameters performed similarly in the subgroups with 
CHD and cardiomyopathy. By contrast, MR-proADM, GDF-15 and sST2 performed poorly. 
When used in conjunction with NT-proBNP, no parameter added significantly to its 
diagnostic accuracy. NT-proBNP, MR-proANP, GDF-15 and sST2 could accurately 
discriminate between patients with preserved and patients with poor functional status. In a 
subset of patients with dilated cardiomyopathy, NT-proBNP, MR-proANP, MR-proADM and 
GDF-15 were associated with poor LV function.  
CONCLUSION: MR-proANP could accurately detect HF in children and adolescents. Its 
diagnostic performance was comparable to that of NT-proBNP, regardless of the underlying 
condition. Reference values are presented. 
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KEY MESSAGES 
 
What is already known about this subject?  
In heart failure (HF), blood-based biomarkers provide objective information on diagnosis, 
prognostic stratification and treatment response. However, validation data and reference 
values of novel parameters are only available for the adult population, where HF is typically 
of ischaemic cause and affects the left ventricle. Findings from adult studies cannot be 
transferred uncritically to the paediatric age group, where important differences in 
pathophysiology must be considered.  
 
What does this study add?  
The present study shows, for the first time, that MR-proANP can be useful for the diagnosis 
of HF in children and adolescents. Its accuracy was independent of the underlying HF 
etiology and was comparable to that of NT-proBNP, the reference standard. By contrast, our 
findings do not support sufficient diagnostic power for MR-proADM, sST2 and GDF-15. 
Reference values from normal children are presented. 
 
How might this impact on clinical practice?  
Measuring biomarkers can aid detect HF, grade disease severity and evaluate response to 
treatment in patients where symptoms are equivocal, which is especially useful in very young 
children or patients with complex lesions, where imaging studies can be difficult to 
accomplish accurately. The reference ranges presented in this study will be of use for future 
research studies and clinical practice. 
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INTRODUCTION 
Paediatric heart failure (HF) differs substantially from its adult counterpart. Contrary 
to the latter, paediatric HF is caused predominantly by the large and heterogeneous group of 
congenital heart diseases (CHD) and by cardiomyopathy (CMP). Advances in CHD 
management have led to a rise in prevalence throughout all age groups.1 These specifics of 
paediatric HF present several problems. Symptoms and history are often ambiguous in young 
children and can be confounded by comorbidities. Functional assessments can be challenging 
in very small or uncooperative children, in complex CHD or in right ventricular (RV) disease, 
where echocardiography is unreliable. Measuring biomarkers in the blood can facilitate HF 
management as they provide objective information on disease severity, prognosis and 
treatment response.2-6  
 
Novel biomarkers typically reflect different components of the complex HF 
pathophysiology such as fibrotic remodelling, myocardial stretch or inflammation, and their 
complementary use has been shown to greatly enhance their prognostic and diagnostic 
power.4 5 7-10 In adult cardiology, such parameters are usually studied and validated in 
relatively homogeneous populations of aged and multi-morbid patients with left-sided HF of 
predominantly ischaemic aetiology.4 7-9 Findings from adults cannot be extrapolated to 
children as they fail to reflect important differences in pathophysiology and compensatory 
reserve inherent to this group. We therefore sought to assess four novel biomarkers in 
paediatric HF patients and to provide reference values from normal children. 
 
METHODS 
Study design and population 
This study was conducted as a prospective trial in two tertiary centres in Austria and 
the United Kingdom. Patients aged 0-24 years were recruited from a cardiac ward and an HF 
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outpatient clinic between September 2013 and July 2015 (n=114). This included a subset of 
patients with dilated CMP (DCM) undergoing elective cardiac magnetic resonance (CMR) 
imaging (n=25). HF was defined as presence of HF symptoms and abnormal ventricular 
systolic function or, in clinically compensated patients without symptoms (i.e. functional class 
I; see below), history of structural heart disease and abnormal ventricular systolic function on 
echocardiography or CMR. Abnormal systolic ventricular function was defined as fractional 
shortening (FS) < 28% or ejection fraction (EF) < 55% for the left ventricle (LV) and EF < 
50% or a Z-score > 2 for tricuspid annular positive systolic excursion (TAPSE) for the right 
ventricle (RV).11 Patients with prior surgery for CHD were excluded if normal cardiac 
physiology had been completely restored. Reference values were obtained from children 
without heart disease undergoing phlebotomy prior to an elective procedure (n=89). 
Exclusion criteria were known renal, pulmonary, autoimmune or malignant comorbidity, 
haemodynamic instability and/or failure to provide informed consent. Written, informed 
consent was obtained from all patients and their parents prior to inclusion. The study was 
conducted in conformity with the Declaration of Helsinki and ethical approval was obtained 
from both institutional review boards. 
 
Functional classification  
Disease severity was graded using the Ross classification.12  
 
Biomarker sampling and analysis 
Blood was collected using standard collection techniques on the day of admission in 
inpatients, or on the day of clinic visit in outpatients. Plasma and serum samples were spun 
and frozen on the day of collection and stored at −80°C for batch-analysis. Soluble ST2 
(sST2; Presage® ST2 Assay, Critical Diagnostics, San Diego, CA, USA) and Growth 
Differentiation Factor 15 (GDF-15; Human GDF-15 Quantikine ELISA Kit, R&D Systems, 
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Minneapolis, MN, USA) were measured in patient sera using a specific enzyme-linked 
immunosorbent assays (ELISA). The measurement range was 3.125 to 200 ng/mL for the 
Presage® ST2 Assay (based on a 50-fold dilution of patient samples) and 23.40 to 1,500 
pg/mL for the Human GDF-15 Quantikine ELISA Kit (based on a 4-fold dilution). An 
automated immunofluorescent assay (KRYPTOR® System, BRAHMS AG, 
Hennigsdorf/Berlin, Germany) was used to determine mid-regional pro-Adrenomedullin 
(MR-proADM) from EDTA-plasma, as well as mid-regional pro-Atrial Natriuretic Peptide 
(MR-proANP), processed from serum. Measurement ranges were: 2.1 to 10,000.0 pmol/L for 
MR-proANP; 0,05 to 100 nmol/L for MR-proADM. N-terminal pro-B Natriuretic Peptide 
(NT-proBNP) was assessed using an Elecsys® immunoassay on a Cobas 8000 system (Roche 
Diagnostics, Mannheim, Germany). Laboratory measurements were performed by 
investigators who were blinded to patient history. 
  
Imaging protocol 
Using echocardiography, LV diameters and volumes were measured in end-diastole 
and end-systole as described (Vivid 9; GE Health Care, Fairfield, CT, USA).13 CMR was 
performed on a 1.5 Tesla system using one spine coil and one body matrix coil (Avanto®, 
Siemens AG, Erlangen, Germany). A vectorcardiogram was used for cardiac gating. 
Ventricular volumes were measured using radial k-t SENSE imaging during free breathing 
and quantified by manual, slice-wise tracing of the endocardial border in systole and diastole 
by inclusion of papillary muscles and trabeculae in the myocardium (OsiriX; Pixmeo SARL, 
Bernex, Switzerland). EF was calculated and Z-scores for LV volumes and diameters 
obtained from published reference data.13-15 
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Statistical analysis 
All statistical analyses were performed by a statistician (M.W.) using the pROC 
package for R (R Foundation for Statistical Computing, Vienna, Austria)16 and SPSS 
Statistics software version 23.0 (IBM Corp., Armonk, NY, USA). Reference intervals were 
calculated according to the Clinical and Laboratory Standards Institute (CLSI) guideline C28-
A3 using MedCalc version 12.5 (MedCalc Software bvba, Ostend, Belgium).17 Due to the 
non-normal distribution and the number of reference values of less than 120 the 
recommended “robust method” of calculation was applied for all parameters. Metric and 
normally distributed data are presented as mean ± standard deviation. In case of skewed data 
distribution, medians are presented with their interquartile range (IQR). Due to data 
skewedness in the reference population, associations between biomarker levels and age or 
functional data were assessed using Spearman’s rank correlation. This population was 
subsequently divided into four age groups and the variance between the biomarker levels of 
these groups was assessed by Kruskal-Wallis test. In order to assess the association between 
biomarker levels and LV size and systolic function in patients with DCM, a binary variable 
was created, whereby LV dysfunction was defined as EF < 55% or FS < 28% and LV 
dilatation as a Z-score > 2 for LVEDV. The associations between biomarkers and these 
factors were determined by logistic regression in this subgroup. To examine the accuracy of 
each blood test to detect HF, a receiver-operating characteristic (ROC) was plotted and the 
area under the curve (AUC) quantified. 95% confidence intervals (CI) were obtained from a 
bootstrap sample of n=10,000.  This procedure was subsequently repeated in subgroups of 
patients with CHD and CMP separately. In order to assess the incremental value of using 
novel parameters in conjunction with NT-proBNP, a step-wise multiple logistic regression 
model was first built. When a statistically significant association with HF was present, the 
resulting value from this model was used to repeat the ROC analysis and the diagnostic 
accuracy of combinations of biomarkers was compared to that of NT-proBNP as a standalone 
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parameter according to the method proposed by de Long et al.18 A significance level of p ≤ 
0.05 was defined for all statistical operations. 
 
RESULTS 
Study population 
 A total of 203 subjects were enrolled for the study (95 female; median age 7.5 years; 
IQR 2.4 – 13.0; range 5 days to 24 years). This included 114 patients with HF (59 female; 
median age 5.9 years; IQR 2.1 – 12.5) and 89 controls (36 female; median age 8.9 years; IQR 
2.7 – 14.5). No significant differences in sex or age distribution were found between the 
groups. Clinical data are listed in Table 1. 
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Table 1. Study population characteristics. 
Ross / NYHA I and II* 88 (77%) 
Ross / NYHA III and IV* 17 (15%) 
Dilated cardiomyopathy 38 (33%) 
Functional single ventricle 15 (13%) 
Pulmonary / right-sided obstruction 11 (10%) 
Aortic / left-sided obstruction 10 (9%) 
Ventricular septal defect 9 (8%) 
Tetralogy of Fallot 8 (7%) 
Atrioventricular septal defect 4 (4%) 
Patent arterial duct 4 (4%) 
Hypertrophic cardiomyopathy 3 (3%) 
Restrictive cardiomyopathy 2 (2%) 
Atrial septal defect 2 (2%) 
Mixed lesion / other 8 (7%) 
All variables listed as N (%). *Missing functional class in 9 patients. 
 
Diagnostic accuracy of novel biomarkers in the general study population 
 There was a significant difference between groups for NT-proBNP and MR-proANP 
(Table 2). Similar trends for sST2 and GDF-15 did not reach statistical significance. ROC 
analysis was undertaken for MR-proANP, sST2, GDF-15 and NT-proBNP in 114 patients and 
89 controls (Fig. 1a). Five datasets were due to incomplete data. NT-proBNP and MR-
proANP showed very good accuracy, whereas the remaining parameters did not perform 
sufficiently (Table 3). Using an NT-proBNP cut-off value of 94 pg/mL yielded a sensitivity of 
80% and a specificity of 71% with a positive predictive value (PPV) of 78% and a negative 
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predictive value (NPV) of 74%. For MR-proANP, a 48 pmol/L cut-off resulted in a 75% 
sensitivity and a specificity of 70% (PPV 76% and NPV 68%). Due to missing data, adding 
MR-proADM to the head-to-head comparison reduced the number of valid cases to 76 in the 
HF group and 51 controls (Table 4). ROC analysis showed poor accuracy for MR-proADM, 
whereas the outcome for the other parameters did not change significantly (Fig. 1b). When 
comparing their ability to discriminate high from low FC (i.e. I and II vs. III and IV), the 
AUC for NT-proBNP was 0.95 (CI: 0.90 – 0.99, p < 0.001), 0.93 for MR-proANP (CI: 0.84 – 
0.99, p < 0.001), 0.89 for GDF-15 (CI: 0.76 – 0.98, p < 0.001) and 0.76 for sST2 (CI: 0.57 – 
0.92, p = 0.001).  
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Table 2. Biomarker results in patients, controls and subgroups. 
Parameter Controls (n=89) All patients (n=114) Patients with CHD (n=71) Patients with CMP (n=43) 
NT-proBNP (pg/mL) 66 (23–105)* 294 (106–893)* 241 (105–543)* 408 (141–4,758)* 
MR-proANP (pmol/L) 40 (28–53)* 74.1 (47.2–166.7)* 72.8 (47.7–172.9)* 76.2 (44.7–162.1)* 
sST2 (ng/mL) 17.7 (13.7–28.8)# 23.6 (14.2–37.3)# 23.5 (13.7–38.1)# 26.3 (15.1–37.5)# 
GDF-15 (pg/mL) 307 (241–501)† 405 (283–629)† 405 (286–591)† 374 (277–707)† 
MR-proADM (nmol/L) 0.34 (0.30–0.40) 0.37 (0.32–0.48) 0.37 (0.32–0.45) 0.37 (0.31–0.51) 
Biomarker results for controls, patients with heart failure as well as subgroups with congenital heart disease (CHD) and cardiomyopathy (CMP). 
All data are presented as medians with interquartile range. Groups by Kruskal-Wallis test. * p < 0.001; † p = 0.070; # p = 0.068. NT-proBNP = 
N-terminal pro-B natriuretic peptide; MR-proANP = mid-regional pro-atrial natriuretic peptide; GDF-15 = Growth differentiating factor 15; 
MR-proADM = mid-regional pro-Adrenomedullin. 
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Table 3. Receiver-operating analysis for heart failure biomarkers (without MR-proADM) 
Parameter All patients (n=114) Patients with CHD (n=71) Patients with CMP (n=43) 
AUC 95% CI p AUC 95% CI p AUC 95% CI p 
NT-proBNP 0.82 0.75 – 0.88 < 0.001 0.81 0.72 – 0.88 < 0.001 0.84 0.75 – 0.92 < 0.001 
MR-proANP  0.76 0.70 – 0.84 < 0.001 0.76 0.69 – 0.86 < 0.001 0.76 0.66 – 0.86 < 0.001 
sST2  0.60 0.52 – 0.69 < 0.05 0.59 0.53 – 0.72 0.051 0.60 0.47 – 0.69 0.063 
GDF-15  0.58 0.50 – 0.67 0.051 0.58 0.48 – 0.68 0.104 0.59 0.47 – 0.69 0.101 
NT-proBNP + GDF-15 0.82 0.75 – 0.88 1.000 0.80 0.72 – 0.88 1.000 0.84 0.75 – 0.92 1.000 
MR-proANP + GDF-15 0.80 0.73 – 0.86 0.585 0.80 0.71 – 0.87 0.887 0.81 0.71 – 0.89 0.399 
NT-proBNP + 
MRproANP + GDF-15 
0.84 0.78 – 0.90 0.359 0.83 0.76 – 0.90 0.372 0.81 0.71 – 0.89 0.399 
Diagnostic performance of biomarkers for the diagnosis of heart failure (HF) in all patients and subgroups with congenital heart disease 
(CHD) and cardiomyopathy (CMP). A receiver-operating characteristic was plotted and the area under the curve (AUC) measured in order 
to compare accuracies between tests. 95% confidence intervals (CI) were obtained from a bootstrap sample of n=10,000. NT-proBNP = N-
terminal pro-B natriuretic peptide; MR-proANP = mid-regional pro-atrial natriuretic peptide; GDF-15 = Growth differentiating factor 15; 
MR-proADM = mid-regional pro-Adrenomedullin. 
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Table 4. Receiver-operating analysis for heart failure biomarkers (with MR-proADM). 
Parameter All patients (n=114) Patients with CHD (n=71) Patients with CMP (n=43) 
AUC 95% CI p AUC 95% CI p AUC 95% CI p 
NT-proBNP 0.84 0.76 – 0.88 < 0.001 0.84 0.75 – 0.88 < 0.001 0.83 0.76 – 0.91 < 0.001 
MR-proANP  0.80 0.70 – 0.84 < 0.001 0.81 0.69 – 0.84 < 0.001 0.79 0.66 – 0.85 < 0.001 
sST2  0.60 0.52 – 0.69 0.058 0.56 0.50 – 0.68 0.328 0.64 0.49 – 0.71 0.026 
GDF-15  0.57 0.51 – 0.68 0.204 0.57 0.50 – 0.68 0.249 0.56 0.50 – 0.68 0.324 
MR-proADM 0.61 0.48 – 0.69 0.029 0.62 0.50 – 0.73 0.066 0.61 0.49 – 0.73 0.066 
 
Diagnostic performance of biomarkers for the diagnosis of heart failure (HF) in all patients and subgroups with congenital heart disease 
(CHD) and cardiomyopathy (CMP). A receiver-operating characteristic was plotted and the area under the curve (AUC) measured in order 
to compare accuracies between tests. 95% confidence intervals (CI) were obtained from a bootstrap sample of n=10,000. NT-proBNP = N-
terminal pro-B natriuretic peptide; MR-proANP = mid-regional pro-atrial natriuretic peptide; GDF-15 = Growth differentiating factor 15; 
MR-proADM = mid-regional pro-Adrenomedullin. 
 15 
Diagnostic accuracy in congenital heart disease 
 Biomarker levels and age did not differ significantly between patients with 
univentricular and biventricular physiology (Table 5). NT-proBNP and MR-proANP 
displayed good accuracy in detecting HF, whereas the other parameters performed poorly 
(Table 3; Fig. 1d). Using an NT-proBNP cut-off value of 94 pg/mL yielded a sensitivity of 
82% and a specificity of 70%, giving a PPV of 68% and a NPV of 83%. For MR-proANP, a 
48 pmol/L cut-off resulted in a 75% sensitivity and a specificity of 71% (PPV 67% and NPV 
78%). Adding MR-proADM to the analysis reduced the number of valid cases to 38 in the HF 
group and 51 controls (Table 4). This revealed an unsatisfactory diagnostic power for MR-
proADM, while that of the other parameters did not change significantly (Fig. 1e). 
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Table 5. Biomarker data and surgical history of CHD patients. 
 Patients with CHD (n=71) 
Univentricular (n=15) Biventricular (n=56) 
Age (years) 4.3 (2.5–12.6) 3.5 (0.5–9.9) 
Functional Class I/II 8 48 
Functional Class III/IV 3 5 
NT-proBNP (pg/mL) 292 (163–422) 228 (103–645) 
MR-proANP (pmol/L) 71.6 (49.4–146.8) 74 (46.1–200.7) 
sST2 (ng/mL) 26.9 (20.2–48.8) 21.0 (12.1–33.6) 
GDF-15 (pg/mL) 416 (336–638) 391 (260–585) 
MR-proADM (nmol/L) 0.38 (0.32–0.42) 0.36 (0.32–0.45) 
Underwent surgery 15 14 
Type of procedure    
 Glenn 7 Pulmonary valve or Fallot repair 5 
 Fontan 4 Coarctation repair 4 
 BT-Shunt 4 Pulmonary artery banding 4 
    Other 1 
Age and biomarker levels did not differ significantly between patients with univentricular 
and biventricular physiology (p > 0.05). NT-proBNP = N-terminal pro-B natriuretic peptide; 
MR-proANP = mid-regional pro-atrial natriuretic peptide; GDF-15 = Growth differentiating 
factor 15; MR-proADM = mid-regional pro-Adrenomedullin. 
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Diagnostic accuracy in cardiomyopathy 
 In the CMP subgroup, ROC analysis showed good performance for NT-proBNP and 
MR-proANP (Table 3, Fig. 1g) but not for the remaining parameters. The addition of MR-
proADM reduced the case number to 38 patients and showed poor accuracy for MR-
proADM, whereas the performance of the other parameters did not change significantly 
(Table 4, Fig. 1h). Using an NT-proBNP cut-off value of 134 pg/mL yielded a sensitivity of 
77% and a specificity of 82% (PPV 67% and NPV 88%). For MR-proANP, a 51 pmol/L cut-
off resulted in 74% sensitivity and a specificity of 74% (PPV 58% and NPV 86%).  
 
In 25 DCM patients with available CMR data, significant correlation of LV EF was 
found with NT-proBNP (r = –0.59, p < 0.01), MR-proANP (r = –0.67, p < 0.001), GDF-15 (r 
= –0.62, p < 0.001) and MR-proADM (r = –0.45, p < 0.05), whereas correlation with sST2 
failed to reach statistical significance (r= –0.29, p = 0.167). Significant correlation with 
LVEDV was found for NT-proBNP (r = 0.50, p < 0.05) and MR-proANP (r = 0.46, p < 0.05). 
In the regression model of all 38 DCM patients with available imaging data, only NT-proBNP 
was predictive of LV dilatation (B = 0.003, CI: 0.002 – 0.005, p < 0.05). This was 
independent of age. Moreover, age-adjusted NT-proBNP and sST2 were predictive of LV 
dysfunction (NT-proBNP: B = 0.001, CI: 0.0001 – 0.002, p < 0.05; sST2: B = 0.003; CI: 
0.0001 – 0.006, p < 0.05). When removed from the model, higher age remained an 
independent predictor for poor LV function (B = 0.10, CI: 0.014 – 0.19, p < 0.05).  
 
Combined use of HF biomarkers 
 In the regression model, the combinations of NT-proBNP and GDF-15, MR-proANP 
and GDF-15 as well as that of all three parameters were good predictors of HF. However, no 
combination yielded a significant increment in AUC over NT-proBNP as a standalone 
parameter (Table 3; Fig. 1c, 1f and 1i). 
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Reference values and association with sex and age 
 Reference values are presented in Table 6. Significant correlation with age was found  
for sST2 (r = 0.278, p < 0.01) and MR-proANP (r = –0.221, p < 0.05). Moreover, there were 
trends for GDF-15 (r = –0.192, p = 0.072) and NT-proBNP (r= –0.205, p = 0.055). NT-
proBNP and MR-proANP showed peaks in the first year, whereas GDF-15 and MR-proADM 
were highest in children aged six years and younger (Table 7). By contrast, sST2 was highest 
in the age group of twelve years and older. Females had significantly higher levels of sST2 
and MR-proANP, though for the latter, this difference was only minor. No differences 
between sexes were found for the other blood parameters. 
Table 6. Reference values from healthy children. 
Parameter 
 
N 95% Reference 
Interval 
Lower Limit 
90% CI 
Upper Limit  
90% CI 
NT-proBNP (pg/mL) 
 
88 < 258 - 178 – 326 
MR-proANP (pmol/L) 
 
88 < 115.9 - 82.4 – 144.8 
sST2 (pg/mL) 
 
89 < 44.4 - 38.2 – 50.0 
GDF-15 (pg/mL) 
 
89 < 1,736 - 1,059 – 2,269 
MR-proADM (nmol/L) 
 
52 0.16 – 0.53 0.12 – 0.20 0.47 – 0.57 
Reference intervals were calculated according to the Clinical and Laboratory 
Standards Institute (CLSI) guideline C28-A3. Due to the non-normal distribution and 
the number of reference values of less than 120 the recommended “robust method” of 
calculation was applied for all parameters.  
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Table 7. Values from normal children and association with age and sex. 
Parameter N Mean Standard deviation p-value 
NT-proBNP (pg/mL) 88 103.1 158.9  
Female 36 81.2 119.3 
0.104# 
Male 52 118.2 180.9 
< 1 year 10 229.4 250.0 
< 0.001† 
1 - 6 years 23 105.4 72.4 
6 - 12 years 24 82.3 77.2 
> 12 years  31 76.6 199.2 
MR-proANP (pmol/L) 88 49.6 46.7  
Female 35 48.3 43.9 
0.008# 
Male 53 50.5 48.8 
< 1 year 10 78.0 68.5 
< 0.001† 
1 - 6 years 24 59.2 31.9 
6 - 12 years 24 34.5 19.8 
> 12 years  30 44.6 58.2 
sST2 (ng/mL) 89 22.4 14.9  
Female 36 26.3 16.9 
0.042# 
Male 53 19.8 12.8 
< 1 year 10 18.6 10.2 
0.228† 
1 - 6 years 24 19.9 12.0 
6 - 12 years 24 18.7 12.7 
> 12 years  31 28.6 18.0 
GDF-15 (pg/mL) 89 572.4 851.3  
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Female 36 567.1 886.4 
0.593# 
Male 53 575.9 835.1 
< 1 year 10 661.1 393.9 
< 0.001† 
1 - 6 years 24 917.2 1,197.4 
6 - 12 years 24 286.1 163.4 
> 12 years  31 498.4 889.1 
MR-proADM (nmol/L) 52 0.35 0.09  
Female 21 0.33 0.09 
0.445# 
Male 31 0.36 0.09 
0 - 6 years 18 0.39 0.10 
0.167† 6 - 12 years 17 0.32 0.09 
> 12 years  17 0.34 0.07 
†Assessed by Kruskal-Willis test and # by Mann-Whitney-U test. 
NT-proBNP = N-terminal pro-B natriuretic peptide; MR-proANP = mid-regional pro-
atrial natriuretic peptide; GDF-15 = Growth differentiating factor 15; MR-proADM = 
mid-regional pro-Adrenomedullin. 
 
DISCUSSION 
The present study is the first to demonstrate the diagnostic utility of MR-proANP in 
the diagnosis of paediatric HF, irrespective of the underlying cause. By contrast, MR-
proADM, GDF-15, and sST2 did not perform sufficiently, and even when used in conjunction 
with the reference standard, NT-proBNP, none of the novel parameters added significantly to 
its diagnostic properties. 
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Only two studies have previously addressed the potential role of MR-proANP in 
paediatric cardiovascular disease.3 19 In adults, it was shown to be superior to NT-proBNP in 
the diagnosis and prognostic stratification of HF in elderly and overweight patients, where 
NT-proBNP is less reliable.4 7 In our study, the performance of NT-proBNP was slightly 
superior to that of MR-proANP and our findings underpin previous work that demonstrated 
good diagnostic accuracy in a broad spectrum of cardiovascular abnormalities of the 
paediatric age.2 6 Increases in MR-proANP and NT-proBNP are attributed to closely related 
physiological mechanisms and the causes underlying the disparity in their diagnostic power 
can only be speculated about. MR-proANP is typically elevated as a consequence of raised 
atrial wall stretch, whereas NT-proBNP increases predominantly in response to ventricular 
wall stretch.20 Moreover, cytokines have been found to influence NT-proBNP expression and 
secretion, while that of MR-proANP appears to be unaffected.21 Age-specific differences in 
filling pressures, atrial wall stretch and cytokine activity could account for the differences in 
the diagnostic performance of these two parameters observed in our study.  
 
Adult HF is predominantly caused by ischaemic heart disease, a condition typically 
associated with a chronic state of systemic inflammation and an endpoint of fibrotic 
remodelling of the myocardium.5 In children, where CHD is the leading cause, the importance 
and prevalence of such fibrotic processes in different lesions is still poorly understood. This 
may partly explain the lack of diagnostic performance observed for sST2, one of the pivotal 
developments in HF biomarkers. Its clinical utility is well established both as a standalone 
parameter and in combination with NT-proBNP, in acute and chronic HF as well as in CAD.8-
10 22 23 In children, it was found to be elevated in the setting of acute Kawasaki disease where 
it was associated with poor diastolic function. However, sST2 was measured in the context of 
acute inflammation and CAD, which limits inferences for paediatric HF and underpins that 
inflammation is an important factor in its biology.24  
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In adults with CHD, GDF-15 was recently shown to be independently associated with 
elevated pulmonary pressures, poor functional status and cardiac dysfunction.25 26 By contrast, 
paediatric data are sparse, particularly in patients with CMP. In a mixed population of both 
children and adults with Fontan circulation, one group found elevated GDF-15 levels to be 
associated with poor functional status and impaired haemodynamic function. However, their 
findings cannot be uncritically transferred to the general paediatric HF population, which is 
predominantly biventricular in physiology.27 Similar data from Fontan patients were 
published for MR-proADM.28 Our findings are partly in keeping with the work of Norozi et 
al. who found GDF-15 to be associated with low FC and poor function in patients with 
CHD.25 However, their patients were predominantly adults and no effort was undertaken to 
provide details on comorbidities that potentially affect GDF-15 levels (e.g. renal disease). 
Moreover, the authors excluded CMP from the analysis and did not provide reference data 
from healthy controls. The ability of GDF-15 to distinguish between HF patients and controls 
was poor in our population, even though an association with impaired cardiac function was 
observed in the DCM group, as it was with MR-proADM. GDF-15 and MR-proADM can be 
elevated in various conditions and are expressed by different tissues. In cardiomyocytes, 
GDF-15 is secreted in the presence of abnormal loading conditions and metabolic stress, such 
as ischaemia, whereas MR-proADM is produced in response to myocardial stretch among 
other causes.5. Notably, in our study levels of both parameters were significantly lower than 
previously described in adults.7 9 Age-related disparities in compensatory mechanisms, 
medication, comorbidity, cardiac loading conditions and underlying pathology are 
conceivable explanations for this phenomenon. 
 
While paediatric reference values have been published recently for GDF-15 and sST2, 
such normal data for MR-proANP and MR-proADM outside of the neonatal period are 
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largely unavailable.19 29 30 In our reference population, MR-proANP was significantly higher 
in the first year of life, in keeping with previous studies on B-type natriuretic peptides.6 Our 
finding that sST2 levels were higher in females and in older children is inconsistent with 
recently published data from a larger cohort.23 30 As our reference data are overall consistent 
with published work this finding is likely to be incidental in nature. 
 
Limitations 
The inhomogeneity of our cohort in terms of underlying aetiology as well as the 
relatively small proportion of patients with severe HF may have obfuscated some of the 
statistical associations present in specific conditions and did not allow for a meaningful 
analysis of the associations between biomarkers and cardiac function. For this reason, we 
performed a subgroup analysis in a homogeneous group of DCM patients. Moreover, a 
longitudinal analysis would have been problematic to interpret as outcome trajectories vary 
substantially between different diseases in the paediatric age group. Further research is 
required to investigate whether and how reliably these novel biomarkers can predict outcome 
or treatment response in a more narrowly defined population. Finally, larger case numbers are 
needed to generate reliable reference intervals for specific age groups and in particular, our 
sample size may have been underpowered for MR-proADM.  
 
Conclusion 
MR-proANP can accurately detect HF in children and adolescents with CHD and 
CMP, even if well compensated. Its diagnostic performance was comparable to that of NT-
proBNP, regardless of the underlying condition. Further research is warranted to evaluate the 
diagnostic and prognostic significance of these tests in specific paediatric cardiac diseases. 
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